Jubilant Life Sciences has earmarked Rs 550 crore for capital expenditure (capex) in the current financial year.
During a recent conference call, the pharma company’s Chairman Shyam S Bhartia said, “to meet the increased demand in our businesses, we plan to invest about Rs 550 crore in capital expenditure and Rs 300 crore in R&D during the year.”
Bhartia further said the company will continue its efforts to strengthen its balance sheet by reducing debt and improving financial ratios.
According to the Chairman, the company is also looking to grow its revenue and operating profits in FY19 and is banking on growth drivers such as speciality pharmaceuticals, active pharmaceutical ingredient (API) and generics and life science ingredients.
Image Credit : images.financialexpress.com